<h4>Objectives</h4>Mesenchymal stromal cells (MSCs) and low-dose interleukin-2 (IL-2) both have demonstrated efficacy in treating systemic lupus erythematosus (SLE). This evidence concerns the gene IL2 and systemic lupus erythematosus.